交易 Indaptus Therapeutics, Inc. - INDP CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
价差 | - | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.024874% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.002651% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平倉 | Change | Change (%) | 開倉 | High | Low |
---|
Indaptus Therapeutics, Inc. Events
時間(協調世界時) (UTC) | 國家 | 事件 |
---|---|---|
No events scheduled |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
收入 | |||||
总营业费用 | 14.9109 | 7.72911 | 13.829 | 47.109 | 43.328 |
销售/一般/行政费用,总计 | 8.58625 | 5.20596 | 7.089 | 8.287 | 7.926 |
研究与开发 | 6.32466 | 2.52315 | 6.74 | 26.659 | 35.402 |
Depreciation / Amortization | |||||
利息费用(收入) - 净运营 | |||||
Other Operating Expenses, Total | 0 | -1.5 | |||
营业收入 | -14.9109 | -7.72911 | -13.829 | -47.109 | -43.328 |
利息收入(费用),非经营净值 | 0.01772 | -0.165 | 0.163 | -0.089 | |
税前净收入 | -14.3228 | -7.71139 | -14.004 | -46.961 | -43.44 |
税后净收入 | -14.3228 | -7.71139 | -14.128 | -47.599 | -43.543 |
未计算非常项目前的净收益 | -14.3228 | -7.71139 | -14.128 | -47.599 | -43.543 |
净收入 | -14.3228 | -7.71139 | -14.128 | -47.599 | -43.543 |
普通股股东可获收益 (不含非经常性项目) | -14.3228 | -7.71139 | -14.128 | -47.599 | -43.543 |
普通股股东可获收益 (含非經常性項目) | -14.3228 | -7.71139 | -14.128 | -47.599 | -43.543 |
摊薄净收入 | -14.3228 | -7.71139 | -14.128 | -47.599 | -43.543 |
摊薄后加权平均股 | 8.26212 | 4.0906 | 0.86525 | 0.4222 | 0.38991 |
扣除特别项目的每股摊薄盈利 | -1.73355 | -1.88515 | -16.3282 | -112.74 | -111.674 |
每股正常摊薄盈利 | -1.73355 | -1.88515 | -16.3282 | -91.7055 | -111.674 |
其他,净值 | 0.58811 | -0.01 | -0.015 | -0.023 | |
异常费用(收入) | 0 | 13.663 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
总营业费用 | 4.08702 | 3.55255 | 3.86926 | 3.40207 | 3.2185 |
销售/一般/行政费用,总计 | 2.17518 | 1.943 | 2.3631 | 2.10498 | 2.27386 |
研究与开发 | 1.91184 | 1.60955 | 1.50617 | 1.2971 | 0.94464 |
营业收入 | -4.08702 | -3.55255 | -3.86926 | -3.40207 | -3.2185 |
其他,净值 | 0.43125 | 0.08618 | 0.03376 | 0.03692 | |
税前净收入 | -3.65578 | -3.46637 | -3.8355 | -3.36515 | -3.21632 |
税后净收入 | -3.65578 | -3.46637 | -3.8355 | -3.36515 | -3.21632 |
未计算非常项目前的净收益 | -3.65578 | -3.46637 | -3.8355 | -3.36515 | -3.21632 |
净收入 | -3.65578 | -3.46637 | -3.8355 | -3.36515 | -3.21632 |
普通股股东可获收益 (不含非经常性项目) | -3.65578 | -3.46637 | -3.8355 | -3.36515 | -3.21632 |
普通股股东可获收益 (含非經常性項目) | -3.65578 | -3.46637 | -3.8355 | -3.36515 | -3.21632 |
摊薄净收入 | -3.65578 | -3.46637 | -3.8355 | -3.36515 | -3.21632 |
摊薄后加权平均股 | 8.27269 | 8.2586 | 8.2586 | 8.2586 | 8.28409 |
扣除特别项目的每股摊薄盈利 | -0.44191 | -0.41973 | -0.46443 | -0.40747 | -0.38825 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
每股正常摊薄盈利 | -0.44191 | -0.41973 | -0.46443 | -0.40747 | -0.38825 |
利息收入(费用),非经营净值 | 0.00217 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
流动资产总额 | 40.3872 | 14.968 | 13.745 | 43.565 | 56.343 |
现金和短期投资 | 39.1322 | 14.671 | 10.062 | 40.579 | 55.218 |
现金等价物 | 39.1322 | 14.671 | 9.292 | 39.246 | 53.393 |
短期投资 | 0.77 | 1.333 | 1.825 | ||
应收账款总额,净额 | 0.085 | 3.486 | 2.031 | 0.478 | |
Accounts Receivable - Trade, Net | 0.085 | 3.486 | 2.031 | 0.478 | |
Other Current Assets, Total | 0.1484 | ||||
Total Assets | 40.5766 | 20.896 | 21.28 | 61.51 | 64.549 |
Property/Plant/Equipment, Total - Net | 0.17289 | 2.211 | 3.818 | 12.233 | 8.206 |
Total Current Liabilities | 4.60414 | 5.334 | 8.342 | 7.656 | 5.747 |
Payable/Accrued | 4.50768 | 0.368 | 3.507 | 2.849 | 1.854 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 4.37 | 4.835 | 0.02 | 0.033 | |
Total Liabilities | 4.677 | 6.363 | 9.745 | 7.965 | 5.747 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.07286 | 1.029 | 1.403 | 0.309 | 0 |
Total Equity | 35.8996 | 14.533 | 11.535 | 53.545 | 58.802 |
Common Stock | 0.08259 | 0.727 | 0.727 | 0.727 | 0.727 |
Additional Paid-In Capital | 51.4879 | 217.357 | 200.231 | 194.642 | 156.356 |
Retained Earnings (Accumulated Deficit) | -15.6709 | -203.551 | -189.423 | -141.824 | -98.281 |
Other Equity, Total | |||||
Total Liabilities & Shareholders’ Equity | 40.5766 | 20.896 | 21.28 | 61.51 | 64.549 |
Total Common Shares Outstanding | 8.2586 | 1.08032 | 0.44865 | 0.41541 | 0.32595 |
Prepaid Expenses | 1.10665 | 0.212 | 0.197 | 0.955 | 0.647 |
Property/Plant/Equipment, Total - Gross | 10.61 | 11.014 | 18.575 | 13.689 | |
Accumulated Depreciation, Total | -8.399 | -7.196 | -6.342 | -5.483 | |
Other Long Term Assets, Total | 0.01648 | 3.717 | 3.717 | 5.712 | 0 |
Accrued Expenses | 0.09647 | 0.596 | 4.787 | 3.86 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
流动资产总额 | 36.9197 | 40.3872 | 43.8549 | 18.792 | 12.159 |
现金和短期投资 | 36.1778 | 39.1322 | 41.8572 | 16.991 | 10.135 |
现金等价物 | 33.2163 | 39.1322 | 41.8572 | 16.991 | 10.135 |
Prepaid Expenses | 0.74195 | 1.10665 | 1.39767 | 0.801 | 1.024 |
Other Current Assets, Total | 0 | 0.1484 | 0.6 | 1 | 1 |
Total Assets | 37.0866 | 40.5766 | 43.8592 | 20.092 | 17.43 |
Property/Plant/Equipment, Total - Net | 0.15037 | 0.17289 | 0.00434 | 0 | 1.554 |
Other Long Term Assets, Total | 0.01648 | 0.01648 | 1.3 | 3.717 | |
Total Current Liabilities | 3.67966 | 4.60414 | 5.78018 | 5.44 | 5.203 |
Payable/Accrued | 0.40032 | 4.50768 | 5.78018 | 0.397 | 0.183 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 5.043 | 5.02 | |||
Total Liabilities | 3.73017 | 4.677 | 5.78018 | 6.156 | 6.086 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.05052 | 0.07286 | 0.716 | 0.883 | |
Total Equity | 33.3564 | 35.8996 | 38.079 | 13.936 | 11.344 |
Common Stock | 0.08259 | 0.08259 | 0.08133 | 0.727 | 0.727 |
Additional Paid-In Capital | 52.3191 | 51.4879 | 50.4523 | 228.421 | 218.397 |
Retained Earnings (Accumulated Deficit) | -19.036 | -15.6709 | -12.4546 | -215.212 | -207.78 |
Total Liabilities & Shareholders’ Equity | 37.0866 | 40.5766 | 43.8592 | 20.092 | 17.43 |
Total Common Shares Outstanding | 8.2586 | 8.2586 | 8.13324 | 1.85874 | 1.12565 |
Accrued Expenses | 0.44466 | 0.09647 | |||
短期投资 | 2.96146 | ||||
Accounts Payable | 2.83468 | ||||
Other Equity, Total | -0.00922 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
净收入/起跑线 | -7.71139 | -14.128 | -47.599 | -43.543 | -28.909 |
经营活动产生的现金 | -11.2905 | -11.511 | -29.045 | -39.076 | -22.132 |
经营活动产生的现金 | 0.0014 | 1.203 | 0.854 | 0.859 | 0.829 |
非现金物品 | 1.49378 | 1.001 | 17.192 | 4.25 | 0.858 |
营运资金的变化 | -5.07433 | 0.413 | 0.508 | -0.642 | 5.09 |
投资活动产生的现金 | 0.44775 | 0.75 | -3.21 | -9.301 | -4.747 |
资本支出 | -0.00385 | -0.022 | -0.921 | -4.667 | -5.001 |
其他投资现金流量项目,总计 | 0.4516 | 0.772 | -2.289 | -4.634 | 0.254 |
融资活动产生的现金 | 48.3375 | 15.978 | 2.368 | 35.059 | 63.707 |
股票的发行(报废),净额 | 27.6565 | 15.907 | 2.368 | 35.059 | 63.707 |
外汇效应 | 0.162 | -0.067 | -0.829 | 0.127 | |
现金净变化 | 37.4947 | 5.379 | -29.954 | -14.147 | 36.955 |
Cash Taxes Paid | 0.0008 | 0.009 | 0.075 | 0.096 | 0 |
融资现金流项目 | 20.681 | 0.071 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -3.36515 | -7.71139 | -4.49506 | -11.661 | -0.61242 |
Cash From Operating Activities | -3.11773 | -11.2905 | -7.75082 | -7.397 | -0.82558 |
Cash From Operating Activities | 0.00053 | 0.0014 | 0.00087 | 1.178 | 0.00021 |
Non-Cash Items | 0.80703 | 1.49378 | 0.83646 | 3.493 | 0.02045 |
Cash Taxes Paid | 0 | 0.0008 | 0.0008 | 0.01 | 0.0008 |
Changes in Working Capital | -0.56014 | -5.07433 | -4.09308 | -0.407 | -0.23382 |
Cash From Investing Activities | -2.79813 | 0.44775 | -0.00385 | 0 | 0 |
Other Investing Cash Flow Items, Total | -2.79813 | 0.4516 | 0 | 0 | |
Cash From Financing Activities | 0 | 48.3375 | 47.9744 | 10.856 | 3.675 |
Financing Cash Flow Items | 0 | 20.681 | 20.681 | 3.675 | |
Net Change in Cash | -5.91585 | 37.4947 | 40.2197 | 3.32 | 2.84942 |
Capital Expenditures | -0.00385 | -0.00385 | 0 | ||
Issuance (Retirement) of Stock, Net | 27.6565 | 27.2934 | 10.856 | ||
Foreign Exchange Effects | -0.139 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
Newman (Michael James) | Individual Investor | 16.2879 | 1368356 | 0 | 2022-08-03 | LOW |
Anderson (Glen R) | Individual Investor | 12.9394 | 1087048 | 348956 | 2022-07-07 | MED |
Lee (Hoonmo) | Individual Investor | 8.2671 | 694522 | 0 | 2021-09-29 | |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.98 | 250348 | 101 | 2022-12-31 | LOW |
The Investment House LLC | Investment Advisor | 1.1383 | 95629 | 0 | 2022-12-31 | LOW |
Meckler (Jeffrey A) | Individual Investor | 0.8972 | 75374 | 10000 | 2022-11-21 | LOW |
Strategy Asset Managers, L.L.C. | Investment Advisor | 0.6587 | 55336 | 0 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.6014 | 50521 | -101 | 2022-12-31 | LOW |
Stratos Wealth Partners, Ltd. | Investment Advisor | 0.3194 | 26832 | 0 | 2022-12-31 | LOW |
Vivaldi Capital Management, LLC | Investment Advisor/Hedge Fund | 0.2857 | 24000 | 0 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2318 | 19473 | 0 | 2022-12-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.2274 | 19100 | -600 | 2022-12-31 | HIGH |
Susquehanna International Group, LLP | Investment Advisor | 0.1725 | 14495 | 14495 | 2022-12-31 | MED |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1141 | 9587 | 0 | 2022-12-31 | LOW |
Tower Research Capital LLC | Hedge Fund | 0.0803 | 6742 | 6418 | 2022-12-31 | HIGH |
Northern Trust Global Investments | Investment Advisor | 0.0394 | 3311 | 0 | 2022-12-31 | LOW |
Litchev (Boyan Vesselinov) | Individual Investor | 0.0137 | 1150 | 500 | 2022-12-01 | HIGH |
Maddaluna (Anthony J) | Individual Investor | 0.008 | 670 | 0 | 2022-08-03 | LOW |
Bangor Savings Bank | Bank and Trust | 0.0048 | 400 | 0 | 2022-12-31 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 0.0043 | 365 | 0 | 2022-12-31 | MED |
交易計算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
貿易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
開倉
平倉
做空 做多
Indaptus Therapeutics, Inc. Company profile
关于 Indaptus Therapeutics Inc.
Indaptus Therapeutics公司,前身为Intec Parent公司,提供免疫疗法来治疗疾病。 该公司致力于开发临床前的候选治疗药物,以产生抗肿瘤和抗病毒反应并治愈疾病。 它通过瞄准特定的肿瘤或病毒抗原来设计其方法。 其主要候选药物Decoy20正处于临床前开发阶段。 其平台是基于这样的假设:要求抗肿瘤免疫疗法同时激活肿瘤和免疫器官的先天和适应性细胞免疫。 其方法是使用多靶点的细菌病原体相关分子模式(PAMPs)包,以减弱和杀死的形式,将完整但不致病的细菌静脉注射。 它的静脉治疗候选药物针对肝脏、脾脏和肿瘤的渗漏血管,在一个免疫器官中产生免疫激活,以及原发性和转移性癌症和乙型肝炎病毒(HBV)感染的共同部位。
Industry: | Biotechnology & Medical Research (NEC) |
3 Columbus Circle
15Th Floor
10019
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球500,000万多名交易者的一份子,选择利用Capital.com进行交易吧。